Accuzith500 mg

Accuzith is a broad-spectrum macrolide (azalide) antibiotic used to treat a range of bacterial infections caused by susceptible organisms. Indications vary by strength of clinical evidence:

Established / FDA-approved uses (adults)

• Acute bacterial exacerbations of chronic bronchitis
• Acute bacterial sinusitis
• Community-acquired pneumonia (mild to moderate, outpatient)
• Pharyngitis/tonsillitis, as an alternative in patients who cannot use first-line therapy
• Uncomplicated skin and skin structure infections
• Non-gonococcal urethritis and cervicitis due to Chlamydia trachomatis
• Genital ulcer disease (chancroid) in men

Established / FDA-approved uses (pediatric, age-dependent)

• Acute otitis media (children 6 months and older)
• Community-acquired pneumonia (children 6 months and older)
• Pharyngitis/tonsillitis (children 2 years and older), as an alternative therapy

Guideline-supported / commonly used indications

• Uncomplicated gonococcal infections, typically as part of combination therapy per current treatment guidelines (not as monotherapy where resistance is a concern)
• Prevention and treatment of Mycobacterium avium complex (MAC) disease in appropriate patients, generally as part of combination regimens
• Traveler's diarrhea in adults (guideline-supported alternative in certain regions/resistance patterns)

Off-label uses (used in practice but not FDA-approved indications)

• Certain sexually transmitted infections in combination regimens per local/international STI guidelines
• Cystic fibrosis-related chronic pulmonary inflammation (anti-inflammatory/immunomodulatory use), under specialist supervision

Accuzith is not appropriate for infections known or strongly suspected to be viral in origin, and its use should be guided by local susceptibility patterns and clinical judgment.

Each formulation of Azithromycin Dihydrate contains azithromycin (as the dihydrate salt) as the active ingredient. It is commercially available in several dosage forms and strengths, including:

• Film-coated tablets (commonly 250 mg and 500 mg)
• Capsules (commonly 250 mg)
• Powder for oral suspension (commonly 100 mg/5 mL and 200 mg/5 mL after reconstitution, and single-dose sachets)
• Powder for injection/infusion (for intravenous use in hospital settings, commonly 500 mg/vial)

Exact strengths and available presentations of Azithromycin Dihydrate vary by manufacturer and market; check the product label for the specific formulation dispensed.

Accuzith is a semi-synthetic macrolide antibiotic belonging to the azalide subclass, structurally derived from erythromycin. It was developed to improve acid stability, tissue penetration, and dosing convenience compared with older macrolides.

Accuzith is widely used because of its long tissue half-life, which allows short-course (typically 3-day) or single-loading-dose, once-daily regimens with good patient compliance. It is active against a broad range of Gram-positive and Gram-negative bacteria, as well as certain atypical organisms such as Chlamydia trachomatis, Mycoplasma pneumoniae, and Legionella pneumophila.

Macrolide antibiotic (azalide subclass) — systemic antibacterial agent. Accuzith belongs to this therapeutic class.

Mechanism of Action

Azithromycin Dihydrate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit (23S rRNA), blocking translocation of peptides during translation and interfering with the assembly of new ribosomal subunits. Depending on the organism and concentration, its action is generally bacteriostatic, though it can be bactericidal against some pathogens at higher concentrations.

Pharmacokinetics

• Absorption: Absolute oral bioavailability is approximately 37-38% (tablet/capsule); food may increase peak plasma concentration of the suspension slightly but does not significantly change overall systemic exposure.
• Distribution: Extensive tissue and intracellular penetration, with tissue concentrations often exceeding plasma concentrations several-fold; plasma protein binding is concentration-dependent (roughly 7-51%).
• Metabolism: Undergoes limited hepatic metabolism (mainly demethylation); metabolites are largely inactive.
• Elimination: Predominantly excreted unchanged via the biliary/fecal route, with a small proportion (about 6%) excreted renally. Terminal elimination half-life is prolonged (approximately 68 hours), reflecting extensive tissue binding, which supports short-course dosing.

• Accuzith tablets and capsules may be taken with or without food; taking with food may reduce mild stomach upset.
• Swallow tablets whole with a glass of water; do not crush unless directed by a pharmacist/physician.
• Oral suspension should be shaken well before each use and measured with an accurate dosing device (not a household spoon).
• Complete the full prescribed course of Accuzith even if you feel better before finishing it.
• If a dose is missed, take it as soon as remembered unless it is close to the next dose; do not double the dose.
• Injectable/intravenous forms of Accuzith are administered only by trained healthcare professionals in a hospital or clinical setting.

Accuzith has fewer clinically significant drug interactions than older macrolides (e.g., erythromycin, clarithromycin) because it has minimal effect on the CYP3A4 enzyme system, but important interactions still exist:

• QT-prolonging drugs (e.g., certain antiarrhythmics such as amiodarone, quinidine, sotalol; some antipsychotics): Concomitant use with Accuzith may increase the risk of QT-interval prolongation and torsades de pointes; avoid combination where possible and monitor if unavoidable. See Precautions and Warnings for full QT-related guidance.
• Warfarin and other oral anticoagulants: Accuzith may potentiate anticoagulant effect; monitor prothrombin time/INR closely during and after co-administration.
• Nelfinavir: Significantly increases azithromycin plasma concentrations; monitor for azithromycin-related adverse effects (liver enzyme abnormalities, hearing changes) if co-administered.
• Digoxin: Macrolides including Accuzith may increase digoxin levels in some patients by altering gut flora that metabolize digoxin; monitor for digoxin toxicity where co-prescribed.
• Ergot derivatives: Theoretical risk of ergotism with macrolide co-administration; avoid concurrent use.
• Aluminum/magnesium-containing antacids: May reduce peak plasma concentration of azithromycin if taken simultaneously; separate dosing by at least 1-2 hours where possible (does not significantly affect total drug exposure).

Most side effects of Accuzith are mild and gastrointestinal, and it is generally better tolerated than older macrolides such as erythromycin.

Common (may affect more than 1 in 20 people)

• Diarrhea/loose stools
• Nausea
• Abdominal pain
• Vomiting
• Headache

Less common

• Dizziness
• Rash
• Mild, reversible elevation of liver enzymes

Rare but serious (seek medical attention promptly)

• Severe allergic reactions (angioedema, severe skin reactions such as Stevens-Johnson syndrome, DRESS syndrome)
• Liver injury or hepatic failure
• QT-interval prolongation, irregular heartbeat (see Precautions and Warnings)
• Clostridioides difficile-associated diarrhea, which can range from mild to life-threatening colitis
• Worsening of myasthenia gravis symptoms
• Hearing loss (usually reversible, reported mainly with high-dose or prolonged use)

Contact your physician if any side effect is severe, persistent, or if you notice signs of an allergic reaction, unusual heartbeat, dark urine, yellowing of the skin/eyes, or severe/persistent diarrhea while taking Accuzith.

Pregnancy

Available human data from decades of use of Accuzith have not shown a clear increased risk of major birth defects or miscarriage, and animal reproduction studies have not shown fetal harm. However, Accuzith should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Consult a physician before use during pregnancy.

Lactation

Accuzith passes into breast milk and may be detectable for an extended period after dosing. Non-serious effects such as diarrhea, vomiting, or rash have been reported in breastfed infants. A physician should be consulted to weigh the benefits of breastfeeding against the possible exposure of the infant, and the infant should be monitored for gastrointestinal symptoms or rash if the mother is taking Accuzith.

• Antibiotic stewardship: Take Accuzith exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.
• QT-interval prolongation: Accuzith has been associated with prolongation of the QT interval and, rarely, torsades de pointes. Use with caution or avoid in patients with known QT prolongation, congenital long QT syndrome, significant bradycardia, uncorrected hypokalemia or hypomagnesemia, or in those taking other QT-prolonging drugs (see Interactions).
• Hepatotoxicity: Cases of hepatotoxicity, including hepatic failure, have been reported. Discontinue promptly if signs or symptoms of liver dysfunction occur (fatigue, jaundice, dark urine, pale stools, abdominal pain, itching).
• Hypersensitivity reactions: Allergic reactions, including angioedema and severe skin reactions, have occurred; some have recurred after symptomatic treatment was stopped. Discontinue immediately if an allergic reaction is suspected.
• Clostridioides difficile-associated diarrhea: May occur during or up to several weeks after treatment with Accuzith; evaluate promptly if diarrhea persists or worsens.
• Myasthenia gravis: May exacerbate symptoms of myasthenia gravis; use with caution and monitor closely in these patients.
• Hepatic impairment: Use with caution, as pharmacokinetics have not been well studied in patients with significant hepatic impairment, and the drug is contraindicated after prior azithromycin-associated cholestatic jaundice.
• Renal impairment: Use with caution in severe renal impairment (see Use in Special Populations).
• Not effective against viral infections such as the common cold or influenza; use only for infections confirmed or strongly suspected to be bacterial.

Symptoms of Accuzith overdose are generally similar to, but more pronounced than, common side effects, and may include severe nausea, vomiting, diarrhea, and transient hearing impairment. In case of a suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to manage an overdose at home. Management is generally supportive and symptomatic, guided by a healthcare professional; there is no specific antidote for Accuzith overdose.

Store Accuzith at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Reconstituted oral suspension should be stored as directed on the label (typically at room temperature, away from direct heat) and any unused portion discarded after the period specified by the manufacturer (commonly 10 days).

Renal Impairment

No dosage adjustment of Accuzith is generally required in mild to moderate renal impairment. Use with caution in patients with severe renal impairment (GFR less than 10 mL/min), as increased systemic exposure has been observed; consult a physician for individualized dosing.

Hepatic Impairment

Pharmacokinetics of Accuzith have not been well established in significant hepatic impairment. Use with caution and clinical monitoring; contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use (see Contraindications).

Elderly

No dosage adjustment is generally required based on age alone, but elderly patients may be more susceptible to QT-interval prolongation and should be monitored accordingly, especially if other risk factors or interacting drugs are present.

Pediatric Patients

See Pediatric Uses for age-specific approved indications and weight-based dosing.

Duration of treatment with Accuzith depends on the indication and typically ranges from a single dose (e.g., for chlamydial urethritis/cervicitis or chancroid) to 3-5 days (e.g., for respiratory tract or skin infections), owing to the drug's long tissue half-life. Some regimens use a single higher loading dose on Day 1 followed by a lower daily dose for several days. The exact duration should be determined by the prescribing physician based on the specific infection, and the full course of Accuzith should always be completed as directed.

For the powder-for-oral-suspension formulation of Accuzith, reconstitute by adding the specified amount of water indicated on the bottle label to the dry powder, then shake well until a uniform suspension forms. Use only the water volume specified for the particular pack size/strength. Once reconstituted, shake well before each dose, use an accurate oral dosing syringe or spoon (not a household spoon), and discard any unused suspension after the period stated on the label (commonly 10 days), storing it as directed (generally at room temperature, away from direct heat and moisture) in the interim. For the powder-for-injection formulation, reconstitution and dilution are performed only by trained healthcare personnel following the manufacturer's instructions for intravenous administration.

Antibacterials; Macrolides; Azalides. Azithromycin Dihydrate is classified within these drug classes.

Azithromycin Dihydrate exerts its antibacterial effect by binding reversibly to the 50S ribosomal subunit of susceptible bacteria, specifically interacting with the 23S ribosomal RNA. This binding inhibits the translocation step of protein synthesis and blocks the formation of new 50S ribosomal subunits, thereby suppressing bacterial protein production. The overall effect is primarily bacteriostatic, although bactericidal activity can occur against certain organisms at higher local concentrations, particularly given the drug's extensive intracellular and tissue accumulation.

B (FDA legacy pregnancy category; current U.S. labeling has transitioned to a narrative risk summary under the Pregnancy and Lactation Labeling Rule)

Safety and effectiveness of Accuzith have been established for specific indications and age groups:

• Acute otitis media: established for children 6 months of age and older.
• Community-acquired pneumonia: established for children 6 months of age and older.
• Pharyngitis/tonsillitis: established for children 2 years of age and older (as an alternative to first-line agents).

Safety and efficacy of Accuzith in infants younger than 6 months have not been established for these indications. Dosing in children is weight-based (mg/kg) and must be calculated and prescribed by a physician; do not exceed the maximum adult dose. If a child vomits shortly after a single large loading dose, re-dosing safety has not been established, and a physician should be consulted before giving a repeat dose.